Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 458

1.

Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD).

Scheef L, Grothe MJ, Koppara A, Daamen M, Boecker H, Biersack H, Schild HH, Wagner M, Teipel S, Jessen F.

Neuroimage Clin. 2019;21:101612. doi: 10.1016/j.nicl.2018.101612. Epub 2018 Nov 27.

2.

Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.

Witte HM, Riecke A, Mayer T, Bartscht T, Rades D, Lehnert H, Merz H, Fetscher S, Biersack H, Gebauer N.

J Cancer Res Clin Oncol. 2019 Jan;145(1):129-136. doi: 10.1007/s00432-018-2772-8. Epub 2018 Oct 16.

PMID:
30327940
3.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

4.

The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma.

Witte H, Biersack H, Kopelke S, Rades D, Merz H, Bernard V, Lehnert H, Fetscher S, Gebauer N.

Br J Haematol. 2019 Mar;184(5):869-873. doi: 10.1111/bjh.15198. Epub 2018 May 22. No abstract available.

PMID:
29785776
5.

Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma.

Witte H, Biersack H, Kopelke S, Rades D, Merz H, Bernard V, Lehnert H, Gebauer N.

Oncotarget. 2018 Apr 13;9(28):19613-19622. doi: 10.18632/oncotarget.24701. eCollection 2018 Apr 13.

6.

Nuclear Medicine Training: Two Different Pathways?

Biersack HJ.

J Nucl Med. 2018 Aug;59(8):1335. doi: 10.2967/jnumed.118.210401. Epub 2018 Mar 15. No abstract available.

7.

Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules.

Yordanova A, Mahjoob S, Lingohr P, Kalff J, Türler A, Palmedo H, Biersack HJ, Kristiansen G, Farahati J, Essler M, Ahmadzadehfar H.

Oncotarget. 2017 Oct 17;8(55):94681-94691. doi: 10.18632/oncotarget.21866. eCollection 2017 Nov 7.

8.

Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.

Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, Biersack HJ, Ezziddin S.

Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83. eCollection 2017.

9.

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC.

Leukemia. 2017 Aug;31(8):1816-1819. doi: 10.1038/leu.2017.124. Epub 2017 Apr 25. No abstract available.

PMID:
28439106
10.

Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors.

Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnerta H, Ungefroren H.

Anticancer Agents Med Chem. 2017;17(10):1351-1356. doi: 10.2174/1871520617666170103094946. Review.

PMID:
28044939
11.

Radionuclide therapy of malignant bone lesions.

Fischer M, Biersack HJ.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):728-729. doi: 10.1007/s00259-016-3574-3. Epub 2016 Dec 9. No abstract available.

PMID:
27942833
12.

Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success.

Sabet A, Strauss AC, Schmolders J, Bornemann R, Sabet A, Oldenburg J, Pennekamp PH, Biersack HJ, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):461-467. doi: 10.1007/s00259-016-3549-4. Epub 2016 Oct 28.

PMID:
27796541
13.

TGF-β Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.

Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Ungefroren H.

Anticancer Agents Med Chem. 2017;17(7):966-972. doi: 10.2174/1871520616666160926110513.

PMID:
27671303
14.

Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.

Sabet A, Binse I, Dogan S, Koch A, Rosenbaum-Krumme SJ, Biersack HJ, Biermann K, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):190-195. doi: 10.1007/s00259-016-3485-3. Epub 2016 Aug 16.

PMID:
27530124
15.

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.

Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP.

Eur J Cancer. 2016 May;58:41-51. doi: 10.1016/j.ejca.2016.01.009. Epub 2016 Mar 2.

PMID:
26943056
16.

Advances in Peptide Receptor Radionuclide Therapy.

Sabet A, Biersack HJ, Ezziddin S.

Semin Nucl Med. 2016 Jan;46(1):40-6. doi: 10.1053/j.semnuclmed.2015.09.005. Review.

PMID:
26687856
17.

Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.

Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Gieseler F, Ungefroren H.

Mol Cancer. 2015 Nov 21;14:199. doi: 10.1186/s12943-015-0468-0.

18.

Discovery of rhenium and masurium (technetium) by Ida Noddack-Tacke and Walter Noddack. Forgotten heroes of nuclear medicine.

Biersack HJ, Stelzner F, Knapp FF.

Nuklearmedizin. 2015;54(6):N50-4. doi: 10.3413/nuk2015050001. Epub 2015 Oct 19.

PMID:
26478117
19.

Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.

Gebauer N, Biersack H, Czerwinska AC, Schemme J, Hardel TT, Bernard V, Rades D, Lehnert H, Luley KB, Thorns C.

Leuk Lymphoma. 2016;57(6):1482-6. doi: 10.3109/10428194.2015.1099648. Epub 2015 Nov 16. No abstract available.

PMID:
26414189
20.

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.

Gebauer N, Biersack H, Czerwinska AC, Schemme J, Hardel TT, Bernard V, Rades D, Lehnert H, Luley KB, Thorns C.

Leuk Lymphoma. 2016;57(1):226-9. doi: 10.3109/10428194.2015.1046863. Epub 2015 Jun 18. No abstract available.

PMID:
25947035
21.

[The role of PET in lung cancer staging].

Gärtner FC, Buermann J, Skowasch D, Biersack HJ, Essler M.

Dtsch Med Wochenschr. 2015 Apr;140(9):679-83. doi: 10.1055/s-0041-101521. Epub 2015 Apr 29. German.

PMID:
25924049
22.

Introduction of a metabolic joint asymmetry score derived from conventional bone scintigraphy. A new tool to differentiate psoriatic from rheumatoid arthritis.

Ezziddin S, Khalaf F, Seidel M, Al Zreiqat A, Wilsmann-Theis D, Simon B, Biersack HJ, Sabet A.

Nuklearmedizin. 2015;54(4):183-9. doi: 10.3413/Nukmed-0698-14-09. Epub 2015 Apr 13.

PMID:
25864944
23.

Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.

Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46. doi: 10.1007/s00259-015-3041-6. Epub 2015 Mar 26.

PMID:
25808630
24.

[SPECT/CT: Benefit and indications of hybrid imaging].

Ahmadzadehfar H, Muckle M, Essler M, Biersack HJ, von Mallek D.

Dtsch Med Wochenschr. 2015 Mar;140(6):434-8. doi: 10.1055/s-0041-101022. Epub 2015 Mar 16. Review. German. No abstract available.

PMID:
25774736
25.

Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.

Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, Mayer K, Biersack HJ, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):370-6. doi: 10.1007/s00259-014-2935-z. Epub 2014 Oct 29.

PMID:
25351506
26.

Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.

Gebauer N, Hardel TT, Gebauer J, Bernard V, Merz H, Feller AC, Rades D, Biersack H, Lehnert H, Thorns C.

Anticancer Res. 2014 Oct;34(10):5503-7.

PMID:
25275047
27.

Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.

Gebauer N, Gebauer J, Hardel TT, Bernard V, Biersack H, Lehnert H, Rades D, Feller AC, Thorns C.

Leuk Lymphoma. 2015 Apr;56(4):1100-6. doi: 10.3109/10428194.2014.944522. Epub 2014 Aug 21.

PMID:
25030036
28.

Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ, Nagarajah J.

J Nucl Med. 2014 Aug;55(8):1260-6. doi: 10.2967/jnumed.114.137166. Epub 2014 May 29.

29.

Significance of multiple nodal basin drainage in patients with truncal melanoma.

Ahmadzadehfar H, Hinz T, Wierzbicki A, Höller T, Habibi E, Wenzel J, Muckle M, Biersack HJ, Essler M, Schmid-Wendtner M.

Q J Nucl Med Mol Imaging. 2016 Sep;60(3):274-9. Epub 2014 May 21.

PMID:
24844255
30.

Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.

Sabet A, Khalaf F, Yong-Hing CJ, Sabet A, Haslerud T, Ahmadzadehfar H, Guhlke S, Grünwald F, Biersack HJ, Ezziddin S.

Nuklearmedizin. 2014;53(2):54-9. doi: 10.3413/Nukmed-0614-13-08.

PMID:
24777355
31.

Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.

Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S.

Nuklearmedizin. 2014;53(2):39-45. doi: 10.3413/Nukmed-0622-13-09.

PMID:
24777354
32.

Appearance of extraosseous pelvic Ewing sarcoma on triphasic bone scan.

Muckle M, Habibi E, Simon B, Zipfel M, Biersack HJ, Ahmadzadehfar H.

Clin Nucl Med. 2014 Apr;39(4):406-8. doi: 10.1097/RLU.0000000000000381.

PMID:
24566405
33.

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack HJ, Sabet A.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33. doi: 10.1007/s00259-013-2677-3. Epub 2014 Feb 7.

PMID:
24504504
34.

Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.

Ahmadzadehfar H, Habibi E, Ezziddin S, Wilhelm K, Fimmers R, Spengler U, Palmedo H, Strunk H, Schild HH, Biersack HJ, Risse J.

Nuklearmedizin. 2014;53(2):46-53. doi: 10.3413/Nukmed-0610-13-07. Epub 2014 Jan 28.

PMID:
24468919
35.

Radioembolization with 90Y resin microspheres for HCC patients with extensive tumor thrombosis into the extrahepatic vessels.

Ahmadzadehfar H, Pieper CC, Ezziddin S, Biersack HJ, Meyer C.

Clin Nucl Med. 2014 Mar;39(3):305-7. doi: 10.1097/RLU.0000000000000367.

PMID:
24458185
36.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

37.

May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.

Sabet A, Khalaf F, Mahjoob S, Al-Zreiqat A, Biersack HJ, Ezziddin S.

Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):80-8. eCollection 2013.

39.

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack HJ, Nagarajah J, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):505-10. doi: 10.1007/s00259-013-2601-x. Epub 2013 Nov 6.

PMID:
24196919
40.

Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Ezziddin S, Sabet A, Yong-Hing CJ, Biersack HJ.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):174-5. doi: 10.1007/s00259-013-2599-0. Epub 2013 Nov 6. No abstract available.

PMID:
24193363
41.

Radium-223 in prostate cancer.

Biersack HJ, Ezziddin S, Knapp FF.

N Engl J Med. 2013 Oct 24;369(17):1659. doi: 10.1056/NEJMc1310231. No abstract available.

PMID:
24152266
42.

Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.

Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Sabet A, Simon B, Pöppel TD, Biersack HJ, Ezziddin S.

Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):437-45. eCollection 2013.

43.

Residual activity after radioembolization of liver tumours with 90Y resin microspheres. A safe calculation method.

Ahmadzadehfar H, Haslerud T, Reichmann K, Meyer C, Habibi E, Fimmers R, Muckle M, Sabet A, Biersack HJ, Ezziddin S.

Nuklearmedizin. 2014;53(3):95-8. doi: 10.3413/Nukmed-0585-13-05. Epub 2013 Oct 9.

PMID:
24105253
44.

Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.

Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, Grünwald F, Biersack HJ.

J Nucl Med. 2013 Dec;54(12):2032-8. doi: 10.2967/jnumed.112.119313. Epub 2013 Oct 7.

45.

Correspondence (letter to the editor): Treatment option not mentioned.

Ezziddin S, Biersack HJ.

Dtsch Arztebl Int. 2013 Sep;110(37):612. doi: 10.3238/arztebl.2013.0612a. No abstract available.

46.

[Delayed effects of oncological therapy].

Biersack H, Brabant G.

Internist (Berl). 2013 Oct;54(10):1221-32. doi: 10.1007/s00108-013-3355-z. Review. German.

PMID:
24062025
47.

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

Sabet A, Haslerud T, Pape UF, Sabet A, Ahmadzadehfar H, Grünwald F, Guhlke S, Biersack HJ, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10. doi: 10.1007/s00259-013-2547-z. Epub 2013 Sep 13.

PMID:
24030668
48.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel T, Guhlke S, Biersack HJ, Ezziddin S.

J Nucl Med. 2013 Nov;54(11):1857-61. doi: 10.2967/jnumed.112.119347. Epub 2013 Sep 5.

49.

Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients.

Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, Vorreuther R, Göhring U, Schild HH, Gerhardt T, Pöge U, Ezziddin S, Biersack HJ, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):59-67. doi: 10.1007/s00259-013-2532-6. Epub 2013 Aug 24.

PMID:
23974666
50.

Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.

Ezziddin S, Reichmann K, Yong-Hing C, Damm M, Risse J, Ahmadzadehfar H, Logvinski T, Guhlke S, Biersack HJ, Sabet A.

Nuklearmedizin. 2013;52(5):170-7. doi: 10.3413/Nukmed-0581-13-05. Epub 2013 Aug 21.

PMID:
23963021

Supplemental Content

Loading ...
Support Center